Duality Advisers LP Grows Holdings in Schrödinger, Inc. (NASDAQ:SDGR)

Duality Advisers LP raised its position in Schrödinger, Inc. (NASDAQ:SDGR) by 12.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,895 shares of the company’s stock after purchasing an additional 6,028 shares during the period. Duality Advisers LP owned about 0.08% of Schrödinger worth $1,482,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Texas Permanent School Fund Corp increased its stake in shares of Schrödinger by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 47,869 shares of the company’s stock valued at $1,292,000 after acquiring an additional 626 shares during the last quarter. Geneos Wealth Management Inc. increased its position in Schrödinger by 70.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 37,126 shares of the company’s stock worth $1,002,000 after purchasing an additional 15,310 shares in the last quarter. GSA Capital Partners LLP increased its position in Schrödinger by 127.7% during the 1st quarter. GSA Capital Partners LLP now owns 39,604 shares of the company’s stock worth $1,069,000 after purchasing an additional 22,210 shares in the last quarter. Baillie Gifford & Co. increased its position in Schrödinger by 0.4% during the 1st quarter. Baillie Gifford & Co. now owns 2,612,007 shares of the company’s stock worth $70,524,000 after purchasing an additional 9,618 shares in the last quarter. Finally, Perigon Wealth Management LLC increased its position in Schrödinger by 14.0% during the 1st quarter. Perigon Wealth Management LLC now owns 9,195 shares of the company’s stock worth $248,000 after purchasing an additional 1,130 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Craig Hallum dropped their target price on shares of Schrödinger from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. SVB Leerink started coverage on shares of Schrödinger in a research report on Tuesday, July 2nd. They set an “outperform” rating and a $29.00 target price for the company. Citigroup decreased their price target on Schrödinger from $39.00 to $37.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. KeyCorp decreased their price target on Schrödinger from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Leerink Partnrs upgraded Schrödinger to a “strong-buy” rating in a report on Tuesday, July 2nd. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.90.

Schrödinger Stock Up 4.2 %

Shares of Schrödinger stock traded up $0.91 on Friday, hitting $22.47. 402,420 shares of the company’s stock traded hands, compared to its average volume of 803,028. The stock has a market cap of $1.63 billion, a P/E ratio of -11.84 and a beta of 1.51. The firm’s 50-day moving average is $21.38 and its 200 day moving average is $25.62. Schrödinger, Inc. has a 52-week low of $18.21 and a 52-week high of $56.47.

Schrödinger (NASDAQ:SDGR) last released its earnings results on Wednesday, May 1st. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). Schrödinger had a negative return on equity of 29.25% and a negative net margin of 75.94%. The company had revenue of $36.60 million during the quarter, compared to analysts’ expectations of $41.23 million. Equities research analysts forecast that Schrödinger, Inc. will post -2.83 EPS for the current year.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.